Total: $62.3M

Year to Date: $119.05M

Company
(Location)

Partner
(Location)

Amt.
(M)

Details

Date


Genmab A/S (Copenhagen, Denmark)

GlaxoSmithKline plc (London)

DKK20 ($3.5)

For the Japanese approval of Arzerra for use in patients with relapsed/refractory CD20-positive chronic lymphocytic leukemia

3/26/13

PolyTherics Ltd. (London)

Celtic Pharma Holdings LP (London)

ND

For further progress on their hematology alliance to produce longer-acting versions of blood factor proteins

3/8/13

Receptos Inc. (San Diego)

Ono Pharmaceutical Co. Ltd. (Osaka, Japan)

ND

For successfully determining a novel protein crystal structure of an undisclosed proprietary G-protein-coupled receptor drug discovery target

3/8/13

ThromboGenics NV (Leuven, Belgium)

Alcon Inc. (unit of Novartis AG; Basel, Switzerland)

€45 ($58.8)

For formal European Union approval for Jetrea for treating patients with vitreomacular traction

3/18/13

Tris Pharma Inc. (Monmouth Junction, N.J.)

Vernalis plc (Winnersh, UK)

ND

For its achievement of proof of concept for the first compound, CCP-01, in the U.S. prescription cough/cold collaboration

3/12/13


Notes:

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed.